Matricelf
Matricelf is a preclinical Israeli biotechnology company developing autologous 3D neural tissue implants that combine patient-derived iPSCs with omentum-derived hydrogel to treat spinal cord injury and other neurological conditions, targeting first-in-human trials in 2027.
- Company typePublic
- Founded2019
- HeadquartersTel Aviv, Israel
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Matricelf does
Matricelf is a preclinical-stage biotechnology company developing a proprietary autologous regenerative medicine platform for central nervous system and other tissue injuries, with a lead program targeting spinal cord injury (SCI). Founded in 2019 at Tel Aviv University by Alon Sinai, PhD, and Professor Tal Dvir, the company is headquartered in Ness Ziona, Israel, and trades on the Tel Aviv Stock Exchange under the ticker MTLF.TA. The core technology combines patient-derived induced pluripotent stem cells (iPSCs) with a thermo-responsive hydrogel derived from decellularized patient omentum tissue to engineer functional 3D neural tissue implants. This fully autologous architecture is designed to eliminate immunogenicity by sourcing both the cellular and scaffold components from the same patient. The lead product is an engineered neural tissue implant intended to bridge damaged spinal tissue and restore motor and sensory function in patients with complete (ASIA-A) SCI.
Matricelf extends its platform into pipeline programs covering stroke, traumatic brain injury (TBI), myocardial infarction, and a proposed wholly-owned Parkinson's disease subsidiary, and has secured three granted U.S. patents covering omentum-based scaffolds (No. 12,514,957, valid through 2034), decellularized omentum tissue particles combined with iPSCs (No. 12,311,075, valid through January 21, 2039), and a calcium-alginate 3D bioprinting support medium (No. 12,221,621, valid through June 2039), plus an allowed application for cardiac tissue 3D printing. Manufacturing is conducted through strategic collaborations with Sheba Medical Center's Advanced Biotherapy Center and Tel Aviv Sourasky Medical Center's Institute for Advanced Cellular Therapies (I-ACT), with Cellino providing AI-driven iPSC production and CiRA Foundation supplying GMP-grade iPSCs. A 248-animal, 39-week GLP safety study completed in June 2026 showed no treatment-related toxicity, tumorigenicity, or implant migration; an IND-enabling efficacy study in 96 animals with chronic SCI is underway, with first-in-human trials targeted for 2027.
Matricelf has no commercial revenue and operates as a clinical-stage development company. Its go-to-market is anchored on clinical development partnerships with leading medical centers, an Israeli Ministry of Health-approved compassionate use program covering up to 8 SCI patients, and an FDA-aligned regulatory pathway. The company completed a USD 24.8 million PIPE financing in October 2025 with qualified and strategic investors, appointed Ron Mayron (former CEO of Teva Israel) as Chairman in February 2026, and is evaluating a potential Nasdaq listing. Revenue mechanics are not yet defined; the autologous, personalized therapy architecture points toward a future one-time-treatment reimbursement model contingent on regulatory approval.
Matricelf firmographics
Firmographics- Name
- Matricelf
- Legal name
- Matricelf Ltd.
- Website
- https://matricelf.com
- Company type
- Public
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Matricelf is a preclinical Israeli biotechnology company developing autologous 3D neural tissue implants that combine patient-derived iPSCs with omentum-derived hydrogel to treat spinal cord injury and other neurological conditions, targeting first-in-human trials in 2027.
- Ownership category
- akta.pro rank
Matricelf industry classification
Industry- Product category
- Regenerative Medicine
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Stem Cell–Based Regenerative Therapies (HLAAAGAA)
- akta.pro secondary industries
- Neural & Spinal Cord Regeneration (HLAAAGAI), Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials) (HLAAAGAB)
Keywords
Where Matricelf is headquartered
LocationHeadquarters
- HQ city
- Tel Aviv
- HQ country
- Israel
- HQ region
- Middle East
Offices1 record
Markets served
Matricelf business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales
Revenue model
- Spinal Cord Injury Treatment: Preclinical-stage company developing personalized regenerative medicine therapies. No commercial revenue yet; developing lead program for spinal cord injury treatment with planned first-in-human clinical trial in 2027.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels6 records
Matricelf product offering
Product offeringCore offering
Matricelf develops a proprietary autologous regenerative medicine platform that combines patient-derived induced pluripotent stem cells (iPSCs) with a personalized decellularized omentum-derived extracellular matrix hydrogel to engineer functional 3D neural tissue implants. Its lead candidate is an engineered neural tissue implant designed to bridge damaged spinal tissue and restore motor and sensory function in spinal cord injury patients, with first-in-human clinical trials targeted for 2027. Pipeline programs apply the same platform to stroke, traumatic brain injury, and myocardial infarction indications.
Product overview
Matricelf is a preclinical-stage biotechnology company developing a proprietary autologous regenerative medicine platform centered on its engineered neural tissue implant for spinal cord injury treatment. The platform combines patient-derived induced pluripotent stem cells (iPSCs) with a personalized extracellular matrix hydrogel derived from the patient's own omentum tissue to create functional 3D neural tissue implants. The core product is an engineered neural tissue implant designed to bridge damaged spinal tissue and restore function. Pipeline programs extend the platform to stroke, traumatic brain injury (TBI), and myocardial infarction. The company also develops 3D bioprinting technology using decellularized omentum tissue for broader tissue engineering applications.
Differentiator
Problem solved
Functional benefit
Products and services
- Engineered Neural Tissue Implant for Spinal Cord Injury
Quantifiable outcome
- Statistically significant motor function improvement in preclinical rat studies: BBB score improved from 2.5 post-injury to 9.1 in treated group vs 5.8 in controls; 80% of treated rats showed >5 BBB points improvement vs 20% in controls
- +1 more outcomes
Companies that use Matricelf
Customer profileSegments3 records
Ideal customer profiles1 record
Matricelf technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature3 records
Matricelf partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core.
- CiRA FoundationcoreCollaborative research agreement to evaluate combining CiRA's GMP-grade iPSCs with Matricelf's neural tissue engineering platform for scalable manufacturing. CiRA Foundation will supply iPSCs from 3 healthy donors to assess feasibility of generating engineered neural tissues using Matricelf's proprietary hydrogel platform. Success criteria include neural marker expression and functional electrical activity. Collaboration aims to develop automated, large-scale manufacturing processes to reduce production costs and improve access to regenerative therapies.
- Sheba Medical CentercoreStrategic collaboration for GMP manufacturing of neural tissue implants and clinical trial readiness. Grants access to cleanroom facility at Advanced Biotherapy Center (ABC). Supports first-in-human clinical trial in spinal cord injury with integrated patient recruitment, manufacturing, surgical implantation, and rehabilitation within a single leading medical center.
- Tel Aviv Sourasky Medical Center (Ichilov)coreAgreement with Institute for Advanced Cellular Therapies (I-ACT) at Tel Aviv Sourasky Medical Center for clinical manufacturing. Enables commencement of clinical-grade manufacturing of autologous neural tissue implants under GMP conditions as part of preparation for first-in-human trials in paralyzed patients.
- CellinocoreGlobal collaboration to advance scalable production of personalized spinal cord injury treatments by combining Cellino's AI-driven Nebula platform with Matricelf's autologous regenerative technology. Cellino produced and delivered autologous iPSCs from four donors, which Matricelf used to generate functional neural tissues showing synchronized electrical activity and key neural markers. Validates compatibility and performance of Cellino's iPSCs with Matricelf's platform.
Scale indicators5 records
Recent moves9 records
Expansion highlights7 records
Matricelf competitors and assessment
Company assessmentDirect peers
- BICO (CELLINK): Leading 3D bioprinting platform company providing bio-inks, bioprinters, and consumables; comparable 3D bioprinting technology category with adjacent regenerative-medicine customer base.
- Organovo: Pioneer in 3D bioprinting of human tissues; comparable technology stack (3D tissue fabrication) although focused on toxicology and liver tissue rather than neural implants.
- Lineage Cell Therapeutics: Cell-therapy biotech developing OPC1 oligodendrocyte progenitor therapy for SCI alongside other CNS indications; closest U.S.-listed pure-play comparable in neural cell therapy for SCI.
- CollPlant Biotechnologies: Israel-based regenerative medicine peer developing recombinant human collagen-based bioinks and tissue implants; same Israeli ecosystem, similar decellularized biomaterial approach, with Matricelf's CTO Tamar Harel Adar previously employed there.
- BrainStorm Cell Therapeutics: Cell-therapy peer (NurOwn autologous MSC platform) targeting neurological indications including SCI and ALS; similar autologous manufacturing paradigm and Israeli roots.
- BioAxone Biosciences: Clinical-stage biotech developing Cethrin (BA-210) and other SCI therapies targeting axonal regeneration; same lead indication (acute/subacute SCI) with overlapping regenerative mechanism.
- InVivo Therapeutics (SiteOne Therapeutics): Direct SCI peer developing implantable biomaterial scaffolds (Neuro-Spinal Scaffold) for acute thoracic SCI; comparable clinical-stage SCI indication, although using a different (acellular polymer scaffold) approach.
Broad incumbents
- Neuralink: Broad-incumbent neurotech competitor pursuing BCI implants for paralysis and SCI; very different modality (electronic implant vs. biological tissue) but targets overlapping SCI patient population and competes for the same payer/regulatory attention.
Others
- Fujifilm Cellular Dynamics: Leading commercial supplier of iPSC-derived cell types; functionally comparable as a supplier to Matricelf's CiRA collaboration and a potential enabler/competitor for the broader iPSC-based therapeutic market.
Regional players
- Pluristem Therapeutics: Israel-based cell-therapy company using placenta-derived adherent stromal cells; same Israeli biotech ecosystem and regenerative-medicine category, though uses allogeneic rather than autologous platform.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Matricelf social profiles
Digital presenceMatricelf financial estimates
Financial estimateRevenue estimate
Valuation estimate
Matricelf leadership team
Management profileNumber of profiles
Profiles9 records
Matricelf subsidiaries and ownership
Company hierarchySubsidiaries1 record
Matricelf funding detail
Funding detailFunding overview
Funding rounds1 record
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Matricelf M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Matricelf
What does Matricelf do?
Matricelf develops a proprietary autologous regenerative medicine platform that combines patient-derived induced pluripotent stem cells (iPSCs) with a personalized decellularized omentum-derived extracellular matrix hydrogel to engineer functional 3D neural tissue implants. Its lead candidate is an engineered neural tissue implant designed to bridge damaged spinal tissue and restore motor and sensory function in spinal cord injury patients, with first-in-human clinical trials targeted for 2027. Pipeline programs apply the same platform to stroke, traumatic brain injury, and myocardial infarction indications.
Is Matricelf a public or private company?
Matricelf is a public company. It is classified as public and is currently operating.
When was Matricelf founded?
Matricelf was founded in 2019. It employs 1 to 10 people.
Where is Matricelf based?
Matricelf is headquartered in Tel Aviv, Israel, in the Middle East region.
How does Matricelf make money?
One revenue line is on record: spinal Cord Injury Treatment.
Who are Matricelf's main competitors?
Direct peers on record are BICO (CELLINK), Organovo, Lineage Cell Therapeutics, CollPlant Biotechnologies, BrainStorm Cell Therapeutics, BioAxone Biosciences and InVivo Therapeutics (SiteOne Therapeutics). Neuralink is listed as a broad incumbent. Fujifilm Cellular Dynamics is listed as an others. Pluristem Therapeutics is listed as a regional player.
Does Matricelf have an API?
No public API is recorded for Matricelf.
What industry is Matricelf in?
Matricelf's product category is Regenerative Medicine. Its primary akta.pro industry code is HLAAAGAA, Stem Cell–Based Regenerative Therapies, with a secondary code of HLAAAGAI, Neural & Spinal Cord Regeneration. Its NAICS code is 541714 and its SIC code is 3841.